A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies
Kalin, Alexander, Medina-Paraiso, Elvia, Ishizaki, Kaoru, Kim, Alex, Zhang, Yannong, Saita, Takanori, Wasaki, MasahikoVolume:
18
Language:
english
Journal:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
DOI:
10.1080/21678421.2017.1362440
Date:
October, 2017
File:
PDF, 491 KB
english, 2017